Reviva Pharmaceutcls Hldgs Inc Financials

RVPH

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows Reviva Pharmaceutcls Hldgs Inc (RVPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

1.24x

For every $1 of reported earnings, Reviva Pharmaceutcls Hldgs Inc generates $1.24 in operating cash flow (-$24.6M OCF vs -$19.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1507.2x

Reviva Pharmaceutcls Hldgs Inc earns $-1507.2 in operating income for every $1 of interest expense (-$20.2M vs $13K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$19.9M

YoY+33.6%

Reviva Pharmaceutcls Hldgs Inc reported -$19.9M in net income in fiscal year 2025. This represents an increase of 33.6% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

13M

Reviva Pharmaceutcls Hldgs Inc had 13M shares outstanding in fiscal year 2025. This represents a decrease of 72.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$11.7M

YoY-48.9%

5Y CAGR+108.8%

Reviva Pharmaceutcls Hldgs Inc invested $11.7M in research and development in fiscal year 2025. This represents a decrease of 48.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RVPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.7M-48.9%	$22.9M-27.1%	$31.4M+37.4%	$22.9M+371.4%	$4.9M+1543.8%	$295K
SG&A Expenses	$8.5M+7.6%	$7.9M-2.4%	$8.1M+50.9%	$5.4M+2.0%	$5.3M+145.5%	$2.1M
Operating Income	-$20.2M+34.4%	-$30.8M+22.0%	-$39.5M-39.9%	-$28.2M-179.4%	-$10.1M-315.0%	-$2.4M
Interest Expense	$13K-27.5%	$18K-45.2%	$34K	N/A	$0-100.0%	$1.5M
Income Tax	$19K-3.2%	$20K+15.1%	$17K-18.4%	$21K+246.1%	$6K+650.5%	$800
Net Income	-$19.9M+33.6%	-$29.9M+23.8%	-$39.3M-38.9%	-$28.3M-231.6%	-$8.5M-125.2%	-$3.8M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.1M-42.8%	$3.7M-9.5%	$4.1M	N/A	$6.9M+22.8%	$5.6M-3.4%	$5.8M	N/A
SG&A Expenses	$1.9M-19.2%	$2.3M-3.2%	$2.4M	N/A	$1.6M-37.0%	$2.5M+19.0%	$2.1M	N/A
Operating Income	-$4.0M+33.6%	-$6.1M+7.1%	-$6.5M	N/A	-$8.5M-4.1%	-$8.1M-2.6%	-$7.9M	N/A
Interest Expense	$3K-45.7%	$5K-58.7%	$12K	N/A	$5K-0.1%	$5K+47.8%	$3K	N/A
Income Tax	$3K-64.3%	$8K+52.6%	$5K	N/A	$0-100.0%	$7K-0.1%	$7K	N/A
Net Income	-$4.0M+33.7%	-$6.1M+5.9%	-$6.4M	N/A	-$8.4M-6.4%	-$7.9M-5.7%	-$7.4M	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RVPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$15.5M-34.6%	$23.7M+25.2%	$18.9M-39.7%	$31.4M+258.4%	$8.8M
Current Assets	N/A	$14.7M-38.0%	$23.7M	N/A	N/A	$44K
Cash & Equivalents	N/A	$13.5M-42.3%	$23.4M+26.2%	$18.5M-37.6%	$29.7M+238.9%	$8.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$14.7M-18.3%	$18.0M+70.8%	$10.5M+287.5%	$2.7M-17.6%	$3.3M
Current Liabilities	N/A	$14.6M-15.0%	$17.2M+72.4%	$10.0M+324.9%	$2.3M+75.9%	$1.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	N/A	$813K-85.8%	$5.7M-31.9%	$8.4M-70.7%	$28.7M+424.8%	$5.5M
Retained Earnings	N/A	-$164.3M-22.3%	-$134.4M-41.3%	-$95.1M-42.3%	-$66.8M-14.6%	-$58.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$14.3M+23.2%	$11.6M+64.4%	$7.1M-54.4%	$15.5M+103.2%	$7.6M-5.3%	$8.1M-40.3%	$13.5M-43.1%	$23.7M
Current Assets	$13.5M+24.9%	$10.8M+72.8%	$6.3M-57.4%	$14.7M+115.6%	$6.8M-5.8%	$7.2M	N/A	$23.7M
Cash & Equivalents	$13.2M+27.2%	$10.4M+95.9%	$5.3M-60.8%	$13.5M+142.4%	$5.6M-10.0%	$6.2M-48.4%	$12.0M-48.8%	$23.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.8M-19.1%	$12.1M+4.8%	$11.5M-21.5%	$14.7M-16.6%	$17.6M+25.0%	$14.1M-5.0%	$14.8M-17.5%	$18.0M
Current Liabilities	$9.7M-19.4%	$12.1M+4.9%	$11.5M-21.2%	$14.6M-16.7%	$17.5M+25.7%	$13.9M-3.8%	$14.5M-15.6%	$17.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.5M+1090.9%	-$459K+89.7%	-$4.5M-648.9%	$813K+108.1%	-$10.0M-65.2%	-$6.0M-348.9%	-$1.3M-123.5%	$5.7M
Retained Earnings	-$180.8M-2.3%	-$176.8M-3.5%	-$170.7M-3.9%	-$164.3M-4.0%	-$158.0M-5.6%	-$149.6M-5.5%	-$141.8M-5.5%	-$134.4M

RVPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$24.6M+26.7%	-$33.5M-18.4%	-$28.3M-49.4%	-$19.0M-77.7%	-$10.7M-162.3%	-$4.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$25.6M+8.1%	$23.7M-28.7%	$33.2M+325.7%	$7.8M-75.3%	$31.6M+146.3%	$12.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$5.6M-11.5%	-$5.0M+38.8%	-$8.2M+10.0%	-$9.1M-114.6%	-$4.2M+50.0%	-$8.5M+27.7%	-$11.7M-32.1%	-$8.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$8.4M-16.6%	$10.1M+138630.0%	$7K-100.0%	$17.0M+369.8%	$3.6M+35.1%	$2.7M+707.4%	$332K-98.8%	$27.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RVPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-3682.0%-2995.5pp	-686.5%-349.9pp	-336.7%-307.0pp	-29.7%+39.5pp	-69.2%
Return on Assets	N/A	-193.0%-27.3pp	-165.7%-16.3pp	-149.3%-122.2pp	-27.1%+16.0pp	-43.2%
Current Ratio	N/A	1.01-0.4	1.38	N/A	N/A	0.03
Debt-to-Equity	N/A	18.08+14.9	3.14+1.9	1.25+1.2	0.09-0.5	0.60
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-88.1%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-28.0%+24.1pp	-52.0%+38.9pp	-90.9%	N/A	-109.7%-12.0pp	-97.6%-42.5pp	-55.1%	N/A
Current Ratio	1.39+0.5	0.90+0.4	0.54-0.5	1.01+0.6	0.39-0.1	0.52	N/A	1.38
Debt-to-Equity	2.15+28.5	-26.34-23.8	-2.59-20.7	18.08+19.8	-1.76+0.6	-2.33+8.7	-11.03-14.2	3.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Kezar Life Sciences KZR

$54.5M

Tenax Therapeutics Inc TENX

$258.2M

Neuphoria Therapeutics Inc NEUP

$23.8M

LakeShore Biopharma Co., Ltd LSB

$25.8M

OnKure Therapeutics OKUR

$58.7M

Frequently Asked Questions

Is Reviva Pharmaceutcls Hldgs Inc profitable?

No, Reviva Pharmaceutcls Hldgs Inc (RVPH) reported a net income of -$19.9M in fiscal year 2025.

What is Reviva Pharmaceutcls Hldgs Inc's operating cash flow?

Reviva Pharmaceutcls Hldgs Inc (RVPH) generated -$24.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

How much does Reviva Pharmaceutcls Hldgs Inc spend on research and development?

Reviva Pharmaceutcls Hldgs Inc (RVPH) invested $11.7M in research and development during fiscal year 2025.

How many shares does Reviva Pharmaceutcls Hldgs Inc have outstanding?

Reviva Pharmaceutcls Hldgs Inc (RVPH) had 13M shares outstanding as of fiscal year 2025.

Are Reviva Pharmaceutcls Hldgs Inc's earnings high quality?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has an earnings quality ratio of 1.24x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Reviva Pharmaceutcls Hldgs Inc cover its interest payments?

Reviva Pharmaceutcls Hldgs Inc (RVPH) has an interest coverage ratio of -1507.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.